BECS

BlueSnap Enhances AR Automation Solution with Compliant Surcharging Solution and Additional Payment Methods to Support the Growing Needs of B2B Businesses

Retrieved on: 
Wednesday, May 22, 2024
Technology, Professional Services, Payments, Finance, B2C, Automation, ACH

BlueSnap , the global payment orchestration platform of choice for leading B2B and B2C businesses, has enhanced their accounts receivable (AR) automation solution with surcharging and additional payment methods to support the growing needs of B2B businesses.

Key Points: 
  • BlueSnap , the global payment orchestration platform of choice for leading B2B and B2C businesses, has enhanced their accounts receivable (AR) automation solution with surcharging and additional payment methods to support the growing needs of B2B businesses.
  • Suppliers and vendors that use AR automation for their B2B businesses see significant improvements in operation by streamlining various aspects of the payment process.
  • AR automation leads to quicker responses and ensures both parties have a clear understanding of invoice and payment statuses.
  • Henry Helgeson, CEO at BlueSnap, says: “We at BlueSnap are always looking for ways to innovate and improve the AR experience for B2B businesses.

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Retrieved on: 
Tuesday, April 16, 2024
Fetus, AMGN, American Thoracic Society, Congress, Arthralgia, ATS, Chronic obstructive pulmonary disease, Emphysema, Pregnancy, Infection, Tezepelumab, PDT, Allergic conjunctivitis, Amgen, Research and development, Back pain, Conference, Placentalia, Vaccine, Miscarriage, Development, Ageing, Helminthiasis, Incidence, Patient, Anaphylaxis, Hypersensitivity, Rash, Pharyngitis, Birth, Asthma, Bronchitis, AstraZeneca, Excipient, Pharmaceutical industry

THOUSAND OAKS, Calif., April 16, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT. 

Key Points: 
  • Overall, tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations versus placebo by 17% (90% CI: −6, 36; p=0.1042).
  • Of note, more reductions were observed in a prespecified subgroup of patients with BEC ≥150 cells/μL (37% [95% CI: 7, 57]).
  • The trend in reduction was greater in a small number of subjects with BEC ≥300 cells/µL.
  • We look forward to presenting the full data set at the congress and based on these findings, we are actively planning for the Phase 3 development of tezepelumab in COPD.

BillingPlatform Adds 700+ Enhancements and Capabilities to its Market-Leading Revenue Lifecycle Management Platform

Retrieved on: 
Wednesday, December 13, 2023
Salesforce, ACSS, Vertex, Research, Forrester Research, Revenue recognition, NetSuite, CPQ, FTP, Growth, OAuth, API, SEPA, Verification, PayPal, Video game, Online shopping, Sovo

DENVER, Dec. 13, 2023 /PRNewswire/ -- BillingPlatform, the enterprise revenue lifecycle management platform for innovative business models, today announced its platform enhancements from the past year designed to support innovative pricing strategies, provide seamless onboarding from competitive or homegrown solutions and provide the scale, security and compliance for global deployments.

Key Points: 
  • BillingPlatform also launched its "Mediation Data Lake," which stores detailed transaction data for increased visibility into details to assist with operational and customer-facing requests.
  • Recognize & Report: BillingPlatform now offers its Revenue Recognition product standalone, independently of the core billing platform.
  • The company added functionality to simplify management of revenue contract changes and delivered new reports to provide additional views of Deferred Revenue over time to support financial reporting and monthly close processes.
  • Additionally, Vertex and Sovos tax engines have improved support capabilities and a new formula assist feature that makes it even easier to tap into the endless flexibility of BillingPlatform.

Infleqtion Launches Oqtant, the World's First Quantum Matter Service to Accelerate the Transition to the Quantum Era

Retrieved on: 
Tuesday, December 5, 2023
Cloud, Electron, Research, Physics, Time (magazine), Time-saving bias, Electronics, University of Bristol, Invention, Quantum engineering, Student, Chief commercial officer, Internet access, University, Bose–Einstein, Q2B, Face, Education, Microscope, Online shopping, Quantum

AUSTIN, Texas, Dec. 5, 2023 /PRNewswire/ -- Infleqtion, the world's leading quantum information company, proudly announces the launch of Oqtant, the world's first quantum innovation platform as a service that provides groundbreaking access to quantum matter for researchers, innovators, and students working on next-generation quantum applications. Oqtant will be used to build more powerful and versatile solutions for new and better sensors, atomtronic circuits, and signal processing, providing the next leap in technology innovation. With access to quantum matter typically out of reach to many, Oqtant will fundamentally democratize quantum discovery and invention. Oqtant provides the core capabilities to create and manipulate matter, anywhere, anytime, by anyone with internet access.

Key Points: 
  • With access to quantum matter typically out of reach to many, Oqtant will fundamentally democratize quantum discovery and invention.
  • "BECs provide the doorway to the quantum era, they are as fundamental to quantum innovation as electrons are to electronics innovation.
  • Oqtant is a critical capability for quantum innovation, research, and education," said Anjul Loiacono, Vice President of Quantum Matter Platforms at Infleqtion.
  • Educational Enhancement: Oqtant facilitates the integration of quantum mechanics and quantum research fundamentals into academic curricula, empowering the next generation of quantum innovators.